- SR3335
-
- $9.80 / 1.79999995231628KG
-
2019-12-23
- CAS:293753-05-6
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100kg
|
Product Name: | SR3335 | Synonyms: | SR3335;SR3335,Thiophene-2-sulfonic acid [4-(2,2,2-trifluoro-1-hydroxy-1-trifluoroMethyl-ethyl)-phenyl]-aMide;ML-176;N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-2-thiophenesulfonamide;hiophene-2-sulfonic acid [4-(2,2,2-trifluoro-1-hydroxy-1-trifluoroMethyl-ethyl)-phenyl]-aMide;ML-176;SR-3335;SR3335;ML-176;SR 3335;SR-3335;ML176;ML 176;SR3335;ML176 | CAS: | 293753-05-6 | MF: | C13H9F6NO3S2 | MW: | 405.3358792 | EINECS: | | Product Categories: | | Mol File: | 293753-05-6.mol | ![SR3335 Structure](CAS/20150408/GIF/293753-05-6.gif) |
| SR3335 Chemical Properties |
storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | solubility | insoluble in H2O; ≥87.4 mg/mL in EtOH; ≥88.8 mg/mL in DMSO | form | solid | color | White to off-white |
| SR3335 Usage And Synthesis |
Description | The retinoic acid receptor-related receptors (RORs) are orphan nuclear receptors with diverse putative roles. SR 3335 is a selective inverse agonist of RORα, competitively inhibiting the binding of 25-hydroxycholesterol to the ligand binding domain (Ki = 220 nM) and inhibiting constitutive transactivation activity (IC50 = 480 nM). It is without effect on RORβ, RORγ, farnesoid X receptor, or liver X receptor α. SR 3335 evokes RORα-dependent effects both in vitro and in vivo, altering gene expression as well as gluconeogenesis. | Definition | ChEBI: N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-thiophenesulfonamide is a sulfonamide. | target | RORα |
| SR3335 Preparation Products And Raw materials |
|